- Conditions
- Dermatitis, Atopic
- Interventions
- tacrolimus ointment, pimecrolimus cream
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 19
- States / cities
- San Diego, California • New Haven, Connecticut • Miami, Florida + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 985–1008
of 10,399
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Postoperative Chylothorax, Congenital Heart Disease, Open Heart Surgery, Chylothorax
- Interventions
- Propranolol Hydrochloride, Placebo
- Drug
- Lead sponsor
- June Wu
- Other
- Eligibility
- 7 Days to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Kidney Failure, Chronic
- Interventions
- Biologic specimens
- Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Malaria, Glucose 6 Phosphate Dehydrogenase Deficiency
- Interventions
- RPQ, SPQ, Primaquine Phosphate, Placebo
- Drug
- Lead sponsor
- University of Mississippi, Oxford
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- University, Mississippi
- Conditions
- Sickle Cell Disease
- Interventions
- Riociguat, Placebo
- Drug
- Lead sponsor
- Mark Gladwin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 20
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Miami, Florida + 17 more
- Conditions
- Methylmalonic Acidemia
- Interventions
- mRNA-3705, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Palo Alto, California • Philadelphia, Pennsylvania
- Conditions
- Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Fanconi Anemia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Monrovia, California
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Chris Goss
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 19
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • Peoria, Illinois + 16 more
- Conditions
- Post-cardiac Surgery, Hyperlactatemia
- Interventions
- Pyruvate levels
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Inherited Metabolic Disorders (IMD)
- Interventions
- MGTA-456
- Drug
- Lead sponsor
- Magenta Therapeutics, Inc.
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Cincinnati, Ohio
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
- Interventions
- Dexamethasone Early, Dexamethasone Late
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 13 Days to 15 Days
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 1994
- U.S. locations
- 13
- States / cities
- Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
- Conditions
- Amyloidosis
- Interventions
- Melphalan, Autologous Stem Cell Transplantation
- Drug · Procedure
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Epidermolysis Bullosa
- Interventions
- Oleogel-S10, Control gel
- Drug
- Lead sponsor
- Amryt Research Limited
- Industry
- Eligibility
- 21 Days and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Miami, Florida + 6 more
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Lovastatin ™, placebo
- Drug · Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 8 Years to 15 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Friedreich Ataxia, Rare Diseases
- Interventions
- Geneticlly confirmed disease causing FXN mutatuion, Healthy Control
- Other
- Lead sponsor
- Friedreich's Ataxia Research Alliance
- Other
- Eligibility
- 4 Years to 21 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Philadelphia, Pennsylvania • Memphis, Tennessee
- Conditions
- Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy 4, SMA
- Interventions
- Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)
- Device
- Lead sponsor
- Marco Capogrosso
- Other
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hypophosphatasia
- Interventions
- Asfotase Alfa
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 12
- States / cities
- Hartford, Connecticut • Chicago, Illinois • Boston, Massachusetts + 9 more
- Conditions
- Sickle Cell Disease, Acute Chest Syndrome
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin
- Interventions
- Apitegromab, Nusinersen, Risdiplam
- Drug
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- Up to 2 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Orange, California • Palo Alto, California + 9 more
- Conditions
- Atopic Dermatitis
- Interventions
- Ruxolitinib phosphate cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 23
- States / cities
- Hoover, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 17 more
- Conditions
- Hyperbilirubinemia, Neonatal
- Interventions
- Stannsoporfin, Placebo, PhotoTherapy (as needed)
- Drug · Other
- Lead sponsor
- InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
- Industry
- Eligibility
- 1 Minute to 48 Hours
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 9
- States / cities
- Colton, California • San Diego, California • Honolulu, Hawaii + 5 more
- Conditions
- Rett Syndrome
- Interventions
- Trofinetide
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 5 Years to 21 Years · Female only
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
- Conditions
- Neonatal Congenital Heart Disease
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 30 Days
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- Shriners Hospitals for Children
- Other
- Eligibility
- 4 Years to 21 Years · Male only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Sacramento, California • Portland, Oregon